Todd Gates, DO
Psychiatry · West Melbourne, FLNPI 1992702260
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $855,752 of the $1,185,244 with a category attached, or 72.2%. AbbVie accounts for 65.4% of it on its own, with 21 other manufacturers making up the rest. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,188 payments — averaging $541.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$775K
- Neurocrine Biosciences, Inc.$238K
- Axsome Therapeutics, Inc.$85K
- E.r. Squibb & Sons, L.L.C.$73K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$7K
- Vanda Pharmaceuticals Inc.$2K
- plus $6K from 16 others
What the payments were for
- Consulting fees$96,2868%
- Speaking & faculty fees$855,75272%
- Travel & lodging$197,16817%
- Food & beverage$36,0153%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 1,224 | $775,350 |
| Neurocrine Biosciences, Inc. | 298 | $237,628 |
| Axsome Therapeutics, Inc. | 111 | $85,013 |
| E.r. Squibb & Sons, L.L.C. | 76 | $72,611 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 106 | $6,888 |
| Vanda Pharmaceuticals Inc. | 67 | $1,583 |
| Alkermes, Inc. | 59 | $1,518 |
| Otsuka America Pharmaceutical, Inc. | 58 | $957 |
| Johnson & Johnson | 37 | $715 |
| Sunovion Pharmaceuticals Inc. | 47 | $633 |
| Teva Pharmaceuticals USA, Inc. | 29 | $632 |
| Lundbeck LLC | 14 | $367 |
| Indivior Inc. | 16 | $331 |
| Biohaven Pharmaceuticals, Inc. | 12 | $315 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $233 |
| Noven Therapeutics, LLC | 12 | $198 |
| Corium, LLC | 1 | $110 |
| Luye Pharma (USA) Ltd. | 3 | $82 |
| Noven Pharmaceuticals, Inc. | 1 | $27 |
| Bausch Health US, LLC | 1 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,185,244 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 121 | $962,733 |
| VraylarCariprazine Hcl | 416 | $591,283 |
| CaplytaLumateperone Tosylate | 223 | $383,661 |
| Abilify MaintenaAripiprazole | 47 | $124,258 |
| AuvelityDextromethorphan Hbr/Bupropion | 96 | $117,596 |
| Invega SustennaPaliperidone Palmitate | 31 | $90,790 |
| TrintellixVortioxetine Hydrobromide | 88 | $68,368 |
| FanaptIloperidone | 23 | $47,709 |
| AristadaAripiprazole Lauroxil | 13 | $44,317 |
| Lurasidone Hcl | 115 | $40,009 |
| Nurtec OdtRimegepant Sulfate | 24 | $30,090 |
| CobenfyXanomeline Tart/Trospium Chlor | 13 | $25,333 |
| SecuadoAsenapine | 13 | $20,848 |
| FetzimaLevomilnacipran Hcl | 23 | $15,094 |
| Quetiapine Fumarate | 499 | $13,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $237,628 | $962,733121 claims |
| AbbVieVraylar, Fetzima | $775,350 | $606,376439 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $6,888 | $383,661223 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $957 | $124,25847 claims |
| Axsome Therapeutics, Inc.Auvelity | $85,013 | $117,59696 claims |
| Johnson & JohnsonInvega Sustenna | $715 | $90,79031 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $233 | $68,36888 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,583 | $47,70923 claims |
| Alkermes, Inc.Aristada | $1,518 | $44,31713 claims |
| E.r. Squibb & Sons, L.L.C.Cobenfy | $72,611 | $25,33313 claims |
| Noven Pharmaceuticals, Inc.Secuado | $27 | $20,84813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in West Melbourne
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
- Jose GamezHialeah$557K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.